Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain and acute eye pain. Chromocell Therapeutics portfolio also includes several novel sublingual and intranasal single-use, disposable spray devices that are intended to treat various conditions including mild to moderate pain, acute migraine and nausea and vomiting associated with chemotherapy and surgery or anesthesia. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media.
Up to 90% verified emails and mobile numbers, refreshed weekly.
Channel Therapeutics operates in the Biotechnology Research industry and is headquartered in United States.
Channel Therapeutics has approximately 2-10 employees employees.
Channel Therapeutics is based in North Brunswick, NJ, United States.
Yes. Channel Therapeutics is a publicly traded company.
You can reach Channel Therapeutics’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.